ArticleAdvances in ophthalmology practice and research
Novel uveal Melanocyte cell lines display distinct features from uveal melanoma.
Article in Advances in ophthalmology practice and research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The latestExpert opinion on drug discovery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purposes: Despite advances in prognostication for uveal melanoma (UM), mortality from this disease remains high due to a lack of effective treatments to prevent metastatic progression. Novel therapeutic targets are needed, but few studies have been able to compare UM to its progenitor cell due to a lack of commercially available uveal melanocyte cell lines. We established novel uveal melanocyte cell lines for comparison to our novel UM patient-derived organoids (PDOs). Methods: Uveal melanocytes were isolated from the choroid of post-mortem donor eyes. Melanocytes were cultured in Ham's F12 medium, and melanocytic markers were confirmed using immunohistochemistry. Melanocytes were grown as spheroids on Cultrex-coated plates prior to Exome- and RNA-sequencing for comparison to UM PDOs. Results: Uveal melanocytes were successfully established with confirmed melanocytic markers and absence of contaminant cell types. Melanocytes displayed regular, higher order growth patterns in 2D culture compared to more primitive colony formation displayed by UM, and melanocytes could be carried for at least 15 passages. Exome-sequencing confirmed an absence of UM-relevant mutations in the melanocytes, and RNA-sequencing revealed differential gene expression between benign uveal melanocytes and UM PDOs. Conclusions: Well-characterized uveal melanocyte cell lines can be compared to UM samples in the laboratory to help identify novel UM treatment targets and serve as a control population for future translation research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.